FILE:BDX/BDX-8K-20080320140153.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers	Financial Statements and Exhibits
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM: Financial Statements and Exhibits
 
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
 
 
           Becton, Dickinson and Company ("BD") has elected John R. Considine as Vice Chairman and Chief Financial Officer of BD, and a member of the Board of Directors, effective March 18, 2008. A copy of the press release issued by BD in connection with Mr. Considine's election is attached hereto as Exhibit 99.1.
 
        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 20, 2008
 
 
 

1 Becton Drive Franklin Lakes, NJ 07417 www.bd.com
 
 
 
Contacts:
Colleen T. White, Corporate Communications  201-847-5369
Patricia A. Spinella, Investor Relations  201-847-5453
 
BD Board of Directors Elects John R. Considine
as Vice Chairman and Member of the Board of Directors
 
Franklin Lakes, NJ (March 18, 2008)
 BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has elected John R. Considine as Vice Chairman and Chief Financial Officer of BD and a member of the Board of Directors, effective immediately. Mr. Considine is currently Senior Executive Vice President and Chief Financial Officer of BD. With his election, the BD Board consists of 14 members, all of whom are independent with the exception of Mr. Considine and Edward J. Ludwig, Chairman, President and Chief Executive Officer.
 
Mr. Considine, 57, joined BD in May 2000 as Executive Vice President and Chief Financial Officer, after spending 17 years at Wyeth in various financial roles including Senior Vice President  Finance of the corporation. He is currently responsible for worldwide finance, information technology, manufacturing, quality and supply chain operations. Mr. Considine will stand for election at BD's Annual Meeting of Shareholders in 2009. He is expected to serve on the Board of Directors until his planned retirement from BD following the 2010 Annual Meeting.
 
"I look forward to working closely with John over the next two years to further our strategy of increasing revenue growth through innovation, complemented by driving operating effectiveness and productivity," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "John has proven his value to the Company, at both the strategic and operational levels, and he will bring unique skills and depth of knowledge to the Board. His contributions will be instrumental in paving the path for BD's continued success, and I look forward to working with him in his expanded role."
 
 more 
 
 
 
 
About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
***
 
 
 
 
 


